Sonlicromanol in Post-COVID
ConditionPost COVID Condition
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMichele van Vugt
About this trial
The aim of this randomized, double-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patients with post-COVID who experience post-exertional malaise (PEM).
Eligibility criteria
Qualifiers
Post COVID according to WHO criteria and verified by post COVID physician
Post-exertional malaise (PEM) according to DSQ-PEM questionnaire
Bell's disability score 20-70%
Mild initial SARS-CoV-2 infection (no hospitalisation)
Disqualifiers
Patients at risk for cardiac conduction disorders
History of clinical significant gastro-intestinal surgery or dysmotility that impairs the adsorption of the IMP
Clinically significant respiratory or cardiovascular disease
Unstable neurological disease
Trial design
Treatments tested in this trial
- Sonlicromanol
- Placebo
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Michele van Vugt
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor institution
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborator
Khondrion BV
Collaborator
Source ClinicalTrials.gov